In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...
The Swiss pharmaceutical giant's plant will produce compounds needed for radioligand therapy (RLT), a form of precision ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...
Zacks Investment Research on MSN
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, ...
Swiss drugmaker Novartis opens new manufacturing facility, part of operations expansion in the U.S. that will also invest ...
Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback